JMIR Publications

ABSTRACT

Background:

Since June 2021, patients with hemophilia A with anti-factor VIII inhibitors and patients with severe hemophilia A without anti-factor VIII inhibitors, and treated with (Hemlibra®), have to choose between the community or the hospital pharmacy. The French center for haemophilia developed the HEMOPHAR e-learning program for the community pharmacists for dispensing Emicizumab.

Objective:

This study aims to evaluate the efficiency and safety of this new care pathway by assessing the HEMOPHAR e-learning program.

Methods:

The methodology is based on the Kirkpatrick's model for evaluating the immediate reaction of the trained community pharmacists (level 1), their level of acquired knowledge (level 2) and their professional practice after 3 months of dispensation (level 3).

Results:

The HEMOPHAR e-learning program reached a large audience with 67% of the eligible community pharmacists. The immediate reaction was overall satisfying. High rates of engagement were reported with 63.5% to 73.3% of completed training modules, and high rates of success with the quizzes with 61.5% to 95.7%. We observed that 83.9% of the community pharmacists needed less than 2 attempts to pass the quiz of the module related to the professional practice while the other quizzes required more attempts. Advice on compliance and drug interactions were the most frequently given to patients by the community pharmacists.

Conclusions:

This study suggests ways to improve the training of community pharmacists and to optimize coordination with treatment centers. This study also reports on the feasibility of switching to a community pharmacy in a secure pharmaceutical circuit, including in the context of a rare disease. Clinical Trial: The PASODOBLEDEMI I study was registered in ClinicalTrials.gov (NCT05449197 related to the evaluation of Reaction, Learning and Behavior).